<DOC>
	<DOCNO>NCT00182520</DOCNO>
	<brief_summary>SRI 's consider first-line treatment OCD , however many patient continue significant symptom despite adequate trial SRI . Neuroimaging study show glutamate neurological system involve OCD . This study test safety efficacy topiramate , drug , target glutamate , treatment OCD , OCD un-responsive , partially responsive regular SRI treatment .</brief_summary>
	<brief_title>Efficacy Adding Topiramate Current Treatment Refractory Obsessive Compulsive Disorder ( OCD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Outpatient primary DSM IV OCD Completion 14week open label trial one follow SRI 's : fluoxetine 80 mg/day , paroxetine 60 mg/day , fluvoxamine 300 mg/day , clomipramine 250 mg/day , sertraline 200 mg/day , citalopram 60 mg/day , escitalopram 30 mg/day demonstrate non partial response SRI treatment ( CGII 3 4 , YBOCS reduction &lt; 35 % ) Stable ( 8 wks long ) concurrent medication include benzodiazepine , sedative hypnotic , antipsychotic , antidepressant . Any primary DSMIV diagnosis ; DSMIV criterion body dysmorphic disorder , bipolar affective disorder , schizophrenia , psychotic disorder , current alcohol/substance abuse . A previous adequate trial topiramate Comorbid major depressive disorder diagnosis predate OCD diagnosis Cognitive behavioural therapy additional psychotherapy past four month Allergy hypersensitivity topiramate BMI &lt; 20 History kidney stone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treatment Refractory Obsessive Compulsive Disorder</keyword>
</DOC>